The intravenous immunoglobulin market in SAM is expected to grow from US$ 783.22 million in 2022 to US$ 1,167.28 million by 2028. It is estimated to grow at a CAGR of 6.9% from 2022 to 2028.
Increasing Geriatric Population
Many of the patients treated with IVIG are above the age of 60 years. With aging, the ability to produce T-cells to fight diseases gets significantly reduced. Thus, an older person’s body is easily prone to several infections and diseases, which increases the demand for immune therapies that involve the use of IVIg. Thus, the increase in the geriatric population across the region is bolstering the intravenous immunoglobulin market.
Market Overview
The SAM intravenous immunoglobulin market is segmented into Brazil, Argentina, and the Rest of SAM. The region held the smallest portion of the market in the global analysis. The intravenous immunoglobulin market in the region is expected to have growth opportunities during the forecast period. The intravenous immunoglobulin market in the SAM region is expected to grow, owing to increased cases of autoimmune diseases and immunodeficiencies, surge in various research activities, increase in awareness, and rise in healthcare expenditure by the countries of the region. Brazil has made huge strides in the healthcare sector, owing to increasing healthcare expenditure. As per the International Trade Administration (ITA), Brazil is the largest healthcare market in Latin America, and it spent 9.1% of its GDP on healthcare in 2020. The intravenous immunoglobulin market in Brazil is expected to flourish, owing to factors such as surge in vaccination programs and rise in healthcare expenditure by the country.
SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 (US$ Million)
SAM Intravenous Immunoglobulin Market Segmentation
The SAM intravenous immunoglobulin market is segmented into type, application, distribution channel, end user, and country. Based on type, the market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment registered the largest market share in 2022.
Based on application, the SAM intravenous immunoglobulin market is segmented into hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment registered the largest market share in 2022. Based on distribution channel, the SAM intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment registered the largest market share in 2022. Based on end user, the SAM intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The hospitals segment registered the largest market share in 2022. Based on country, the market is segmented into Brazil, Argentina, and the Rest of SAM. Brazil dominated the market in 2022.
ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited are among the leading companies operating in the intravenous immunoglobulin market in the region.
At 6.9% CAGR, the SAM Intravenous Immunoglobulin Market is speculated to be worth US$ 1,167.28 million by 2028, says The Insight Partners
According to The Insight Partners’ research, the SAM intravenous immunoglobulin market was valued at US$ 783.22 million in 2022 and is expected to reach US$ 1,167.28 million by 2028, registering a CAGR of 6.9% from 2022 to 2028. Rising prevalence of immunodeficiency diseases and increasing geriatric population are the critical factors attributed to the market expansion.
Intravenous immunoglobulin (IVIG) is used to treat patients suffering from primary and secondary immunodeficiencies and autoimmune disorders. IVIG is a standard therapy to treat most of the primary immunodeficiencies (PID). The rare genetic diseases can be chronic, weakening, and expensive to treat. Immune Thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by abnormally low levels of platelets; a situation referred to as thrombocytopenia. As per the Rare Diseases Organization, around 200,000 ITP cases are recorded across the region annually. Thus, increasing prevalence of immunodeficiency diseases drives the growth of the intravenous immunoglobulin market.
On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of SAM intravenous immunoglobulin market.
Based on type, the SAM intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 29.1% market share in 2022, amassing US$ 227.58 million. It is projected to garner US$ 336.93 million by 2028 to expand at 6.8% CAGR during 2022–2028. Based on application, the SAM intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.7% market share in 2022, amassing US$ 169.84 million. It is projected to garner US$ 261.34 million by 2028 to expand at 7.4% CAGR during 2022–2028. Based on distribution channel, the SAM intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.9% market share in 2022, amassing US$ 437.70 million. It is projected to garner US$ 647.35 million by 2028 to expand at 6.7% CAGR during 2022–2028. Based on end user, the SAM intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.3% market share in 2022, amassing US$ 370.14 million. It is projected to garner US$ 543.19 million by 2028 to expand at 6.6% CAGR during 2022–2028. Based on country, the SAM intravenous immunoglobulin market is segmented into Brazil, Argentina, and the Rest of SAM. Our regional analysis states that Brazil captured 47.3% market share in 2022. It was assessed at US$ 370.14 million in 2022 and is likely to hit US$ 543.19 million by 2028, exhibiting a CAGR of 6.6% during the forecast period. Key players dominating the SAM intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited among others.
In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL's preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company's global new product development programs. The agreement builds on BPL and ARG's previous successful collaboration on clinical trial programs. In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease.
1. Introduction
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 SAM Intravenous Immunoglobulin Market – By Type
1.3.2 SAM Intravenous Immunoglobulin Market – By Application
1.3.3 SAM Intravenous Immunoglobulin Market – By Distribution Channel
1.3.4 SAM Intravenous Immunoglobulin Market – By End User
1.3.5 SAM Intravenous Immunoglobulin Market – By Country
2. SAM Intravenous Immunoglobulin Market– Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. SAM Intravenous Immunoglobulin Market – Market Landscape
4.1 Overview
4.2 SAM PEST Analysis
4.3 Expert Opinion
5. SAM Intravenous Immunoglobulin Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Prevalence of Immunodeficiency Diseases
5.1.2 Increasing Geriatric Population
5.2 Market Restraints
5.2.1 Adverse Effects of Immunoglobulin Therapy
5.3 Future Trends
5.3.1 Strong Pipeline Candidates for IVIG
5.4 Impact Analysis
6. Intravenous Immunoglobulin Market– SAM Analysis
6.1 SAM Intravenous Immunoglobulin Market Revenue Forecast and Analysis
7. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028– by Type
7.1 Overview
7.2 SAM Intravenous Immunoglobulin Market, By Type 2022 & 2028 (%)
7.3 IgG
7.3.1 Overview
7.3.2 IgG Revenue and Forecast to 2028 (US$ Million)
7.4 IgM
7.4.1 Overview
7.4.2 IgM - Revenue and Forecast to 2028 (US$ Million)
7.5 IgA
7.5.1 Overview
7.5.2 IgA - Revenue and Forecast to 2028 (US$ Million)
7.6 IgE
7.6.1 Overview
7.6.2 IgE - Revenue and Forecast to 2028 (US$ Million)
7.7 IgD
7.7.1 Overview
7.7.2 IgD - Revenue and Forecast to 2028 (US$ Million)
8. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Application
8.1 Overview
8.2 SAM Intravenous Immunoglobulin Market, By Application 2022 & 2028 (%)
8.3 Hypogammaglobulinemia
8.3.1 Overview
8.3.2 Hypogammaglobulinemia - Market Revenue and Forecast to 2028 (US$ Million)
8.4 Chronic Inflammatory Demyelinating Polyneuropathy
8.4.1 Overview
8.4.2 Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecast to 2028 (US$ Million)
8.5 Immunodeficiency Diseases
8.5.1 Overview
8.5.2 Immunodeficiency Diseases - Market Revenue and Forecast to 2028 (US$ Million)
8.6 Myasthenia Gravis
8.6.1 Overview
8.6.2 Myasthenia Gravis - Market Revenue and Forecast to 2028 (US$ Million)
8.7 Multifocal Motor Neuropathy
8.7.1 Overview
8.7.2 Multifocal Motor Neuropathy - Market Revenue and Forecast to 2028 (US$ Million)
8.8 Idiopathic Thrombocytopenic Purpura
8.8.1 Overview
8.8.2 Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecast to 2028 (US$ Million)
8.9 Inflammatory Myopathies
8.9.1 Overview
8.9.2 Inflammatory Myopathies - Market Revenue and Forecast to 2028 (US$ Million)
8.10 Specific Antibody Deficiency
8.10.1 Overview
8.10.2 Specific Antibody Deficiency - Market Revenue and Forecast to 2028 (US$ Million)
8.11 Guillain-Barre Syndrome
8.11.1 Overview
8.11.2 Guillain-Barre Syndrome - Market Revenue and Forecast to 2028 (US$ Million)
8.12 Others
8.12.1 Overview
8.12.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
9. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by Distribution Channel
9.1 Overview
9.2 SAM Intravenous Immunoglobulin Market, By Distribution Channel 2022 & 2028 (%)
9.3 Hospital Pharmacy
9.3.1 Overview
9.3.2 Hospital Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)
9.4 Retail Pharmacy
9.4.1 Overview
9.4.2 Retail Pharmacy - Market Revenue and Forecast to 2028 (US$ Million)
9.5 Others
9.5.1 Overview
9.5.2 Others - Market Revenue and Forecast to 2028 (US$ Million)
10. SAM Intravenous Immunoglobulin Market Revenue and Forecast to 2028 – by End User
10.1 Overview
10.2 SAM Intravenous Immunoglobulin Market, By End User 2022 & 2028 (%)
10.3 Hospitals
10.3.1 Overview
10.3.2 Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)
10.4 Specialty Clinics
10.4.1 Overview
10.4.2 Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)
10.5 Others
10.5.1 Overview
10.5.2 Others - Market Revenue And Forecasts To 2028 (US$ Million)
11. SAM Intravenous Immunoglobulin Market Revenue and Forecasts to 2028 – Country Analysis
11.1 Overview
11.1.1 SAM: Intravenous Immunoglobulin Market, by Country, 2022 & 2028 (%)
11.1.1.1 Brazil: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.1 Overview
11.1.1.1.2 Brazil: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.1.3 Brazil: Intravenous Immunoglobulin Market, by Type, 2019–2028 (USD Million)
11.1.1.1.4 Brazil: Intravenous Immunoglobulin Market, by Application, 2019–2028 (USD Million)
11.1.1.1.5 Brazil: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (USD Million)
11.1.1.1.6 Brazil: Intravenous Immunoglobulin Market, by End User, 2019–2028 (USD Million)
11.1.1.2 Argentina: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.1 Overview
11.1.1.2.2 Argentina: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.2.3 Argentina: Intravenous Immunoglobulin Market, by Type, 2019–2028 (USD Million)
11.1.1.2.4 Argentina: Intravenous Immunoglobulin Market, by Application, 2019–2028 (USD Million)
11.1.1.2.5 Argentina: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (USD Million)
11.1.1.2.6 Argentina: Intravenous Immunoglobulin Market, by End User, 2019–2028 (USD Million)
11.1.1.3 Rest of SAM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.1 Overview
11.1.1.3.2 Rest of SAM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
11.1.1.3.3 Rest of SAM: Intravenous Immunoglobulin Market, by Type, 2019–2028 (USD Million)
11.1.1.3.4 Rest of SAM: Intravenous Immunoglobulin Market, by Application, 2019–2028 (USD Million)
11.1.1.3.5 Rest of SAM: Intravenous Immunoglobulin Market, by Distribution Channel, 2019–2028 (USD Million)
11.1.1.3.6 Rest of SAM: Intravenous Immunoglobulin Market, by End User, 2019–2028 (USD Million)
12. SAM Intravenous Immunoglobulin Market–Industry Landscape
12.1 Overview
12.2 Inorganic Growth Strategies
12.2.1 Overview
12.3 Organic Growth Strategies
12.3.1 Overview
13. Company Profiles
13.1 Takeda Pharmaceutical Company Limited
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Grifols, S.A.
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 Pfizer Inc.
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 ADMA Biologics, Inc.
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Bio Products Laboratory Ltd.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Shanghai RAAS
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Octapharma AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
13.8 Kedrion S.p.A
13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments
13.9 CSL Behring (CSL Limited)
13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments
13.10 Prothya Biosolutions B.V.
13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments
14. Appendix
14.1 About The Insight Partners
14.2 Glossary of Terms in Intravenous Immunoglobulin Market
Table 1. SAM Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (US$ Million)
Table 2. Brazil: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 3. Brazil: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 4. Brazil: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 5. Brazil: Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 6. Argentina: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 7. Argentina: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 8. Argentina: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 9. Argentina: Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 10. Rest of SAM: Intravenous Immunoglobulin Market, by Type – Revenue and Forecast to 2028 (USD Million)
Table 11. Rest of SAM: Intravenous Immunoglobulin Market, by Application – Revenue and Forecast to 2028 (USD Million)
Table 12. Rest of SAM: Intravenous Immunoglobulin Market, by Distribution Channel – Revenue and Forecast to 2028 (USD Million)
Table 13. Rest of SAM: Intravenous Immunoglobulin Market, by End User– Revenue and Forecast to 2028 (USD Million)
Table 14. Recent Inorganic Growth Strategies in the Intravenous Immunoglobulin Market
Table 15. Recent Organic Growth Strategies in the Intravenous Immunoglobulin Market
Table 16. Glossary of Terms in Intravenous Immunoglobulin Market
Figure 1. SAM Intravenous Immunoglobulin Market Segmentation
Figure 2. SAM Intravenous Immunoglobulin Market Segmentation, By Country
Figure 3. SAM Intravenous Immunoglobulin Market Overview
Figure 4. SAM Intravenous Immunoglobulin Market, by Type
Figure 5. SAM Intravenous Immunoglobulin Market, by Country
Figure 6. SAM: PEST Analysis
Figure 7. Impact Analysis
Figure 8. SAM Intravenous Immunoglobulin Market– Revenue Forecast and Analysis – 2020 - 2028
Figure 9. SAM Intravenous Immunoglobulin Market, by Type 2022 & 2028 (%)
Figure 10. SAM IgG Revenue and Forecasts to 2028 (US$ Million)
Figure 11. SAM IgM - Revenue and Forecasts to 2028 (US$ Million)
Figure 12. SAM IgA - Revenue and Forecasts to 2028 (US$ Million)
Figure 13. SAM IgE - Revenue and Forecasts to 2028 (US$ Million)
Figure 14. SAM IgD - Revenue and Forecasts to 2028 (US$ Million)
Figure 15. SAM Intravenous Immunoglobulin Market, by Application 2022 & 2028 (%)
Figure 16. SAM Hypogammaglobulinemia - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 17. SAM Chronic Inflammatory Demyelinating Polyneuropathy - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 18. SAM Immunodeficiency Diseases - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 19. SAM Myasthenia Gravis - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 20. SAM Multifocal Motor Neuropathy - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 21. SAM Idiopathic Thrombocytopenic Purpura - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 22. SAM Inflammatory Myopathies - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 23. SAM Specific Antibody Deficiency - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 24. SAM Guillain-Barre Syndrome - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 25. SAM Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 26. SAM Intravenous Immunoglobulin Market, by Distribution Channel 2022 & 2028 (%)
Figure 27. SAM Hospital Pharmacy - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 28. SAM Retail Pharmacy - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 29. SAM Others - Market Revenue and Forecasts to 2028 (US$ Million)
Figure 30. SAM Intravenous Immunoglobulin Market, by End User 2022 & 2028 (%)
Figure 31. SAM Hospitals - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 32. SAM Specialty Clinics - Market Revenue And Forecasts To 2028 (US$ Million)
Figure 33. SAM Others- Market Revenue And Forecasts To 2028 (US$ Million)
Figure 34. SAM: Intravenous Immunoglobulin Market, by Key Country – Revenue (2022) (USD Million)
Figure 35. SAM: Intravenous Immunoglobulin Market, by Country, 2022 & 2028 (%)
Figure 36. Brazil: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 37. Argentina: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
Figure 38. Rest of SAM: Intravenous Immunoglobulin Market – Revenue and Forecast to 2028 (USD Million)
